The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Dominic Cummings' vision for a groundbreaking research agency is gaining momentum with cross-party support and substantial funding. ARIA aims to revolutionize the UK through cutting-edge technologies and entrepreneurial science, seeking its own 'Ozempic moment'.
A recent study highlights a potential issue in online drug advertising. Searching for terms like 'weight loss' can yield results for drugs like Ozempic, even if they are not FDA-approved for that specific purpose, raising concerns about misleading information.
A businesswoman in São Paulo was arrested with two accomplices for allegedly leading a criminal organization involved in the illegal sale of weight loss drugs. The investigation revealed a sophisticated scheme involving online promotion and sales through a perfumery.
The GLP-1 weight loss market is experiencing significant shifts with new leadership and competitive pressures. This article dives into the latest developments surrounding semaglutide, Ozempic, and Wegovy, and explores the broader impact on health and wellness.
New research shows that GLP-1 receptor agonists, often used for diabetes and weight loss, may reduce the risk of certain types of arthritis. This blog post explores the potential benefits of this peptide therapy, offering actionable insights for improved health and wellness.
New Wegovy trial results are making waves, showing impressive weight loss and cardiovascular benefits. Discover how GLP-1 therapies are transforming healthcare.
New data reveals a drop in US obesity rates, and GLP-1 drugs like Ozempic and Wegovy are likely playing a significant role. This post explores the impact of these medications and what it means for your health.
The market for GLP-1 weight loss medications is booming, but it's also highly competitive. This post explores the latest developments, including legal battles and the future of these groundbreaking treatments, and how it impacts your health journey.
Eli Lilly's significant investment in Puerto Rico aims to boost the production of oral GLP-1 medications, like orforglipron, for weight loss and other health benefits. This marks a turning point in accessible treatments for metabolic health. Dive into what this means for you and your wellness journey.
